Annual Securities Report — FY2025
What TERUMO CORPORATION reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-23View the original on EDINET
How much it says
58Typical
What moved here
43named for the first time
Its own wording
53terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
On 29 October 2025, TERUMO CORPORATION acquired OrganOx as a wholly owned subsidiary and added the Organ Technologies Business as a new reportable segment from the current fiscal year. The Company also entered into an agreement in May 2025 to acquire WuXi Biologics’ pharmaceutical-products plant in Leverkusen, Germany, completing the acquisition on 30 September 2025.
Komori's summary of this document, not the document's own words.58Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
91
Very detailed
44
Thin
62
Detailed
0
Almost nothing
65
Detailed
68
Detailed
27
Almost nothing
69
Detailed
53
Typical
55
Typical
73
Detailed
R&D spend0百万円Money spent making new things.
Cash left over-0百万円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
Employees31,185Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.